U.S. Marshals seize products
This article was originally published in The Tan Sheet
Executive SummaryU.S. Marshals on Oct. 31 seized more than $300,000 in General Therapeutic's dietary supplement products and ingredients maintained under "grossly unsanitary conditions," including the NC Solution antifungal product, FDA says. In August and September, FDA inspectors found the St. Louis-based firm was "still manufacturing drugs and dietary supplements under unsanitary conditions, including insects and rodent filth on and around manufacturing equipment, despite a warning by FDA of serious violations in 1999," according to the agency...
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.